The management team and scientific staff hold memberships to several internationally recognized professional scientific organizations, including: Safety Pharmacology Society, British Pharmacological Society, British Physiological Society, Society of Toxicology, International Society for the Study of Xenobiotics
Alfred Botchway, Ph.D., DSP is Founder and President of Xenometrics. Dr. Botchway has numerous years of experience spanning academic research, a major pharmaceutical company and a contract laboratory. His experience includes extensive research in safety pharmacology, and Alfred has monitored and conducted numerous studies on behalf of large pharmaceutical companies. Dr. Botchway has authored scholarly articles (with international circulation), and been profoundly involved with studies in support of INDs. Furthermore, he has served as a reviewer for multiple scientific manuscripts for highly esteemed international scientific journals. In addition to membership of several international scholastic professional scientific organizations, Alfred is an active member of the Safety Pharmacology Society, and having served on the board of directors of the International Safety Pharmacology Society for over 4 years, Dr. Botchway was recently elected as the society’s 2015 President. In addition to his scientific endeavors, he also serves on the State of Kansas’s Council of Economic Advisors. Alfred graduated from Pipeline (an Entrepreneurial Immersion Program with reach across multiple states), and was elected the first President of the Alumni and now serves as a Board member for Pipeline. Dr. Botchway was awarded his Ph.D. in Cardiovascular Physiology at Imperial College of Science, Technology and Medicine, University of London, UK.
Tom Haymaker, BS is Co-Founder and Director of Operations of Xenometrics. Mr. Haymaker adds over 15 years of experience in various facets of research to the team. Subsequent to graduating from Kansas State University, Tom gained a vast amount of experience during his time of service at several research organizations. He has been instrumental in designing, coordination, conducting and reporting of non-clinical pharmacokinetic studies required for evaluating a drug’s potential bioavailability. Tom has worked in collaboration with a diverse spectrum of companies.
Sandra Love, Ph.D. is Director of Pharmacology services at Xenometrics. Dr. Love oversees the company's safety and exploratory pharmacology services. She has more than 20 years of experience in pharmaceutical research and pre-clinical development of new molecular entities for IND submissions. Dr. Love began her career as a research pharmacologist at Marion Laboratories and Marion Merrell Dow. She has held senior positions, including head of cardiac electrophysiology and in-vitro pharmacology at a contract research organization. Dr. Love brings a wealth of experience and leadership to Xenometrics.
Devendra Dandekar, Ph.D. is Director of Toxicology services at Xenometrics. Dr. Dandekar is responsible for the company’s nonclinical Toxicology services working with a wide range of biotechnology and pharmaceutical companies. Dr. Dandekar has more than 15 years of research experience in spanning both academia and industry. Dr. Dandekar holds a BS, MS, and a Ph.D. in Zoology from the Maharaja Sayajirao University of Baroda, India.
Phil Atterson, BS, MS is Director, Project Management at Xenometrics. He has over 30 years’ experience in preclinical safety assessment in a contract research environment primarily focused in Toxicology and Pharmacology. Phil gained his experience and knowledge in CNS and cardiovascular pharmacology, including establishment of one the first laboratories in the world to offer Safety Pharmacology, in a number of roles of increasing responsibility in the Department of Pharmacology at Huntingdon Research Center in the UK (18 years), prior to joining Quintiles Inc; where he held the position of Executive Director, Safety Pharmacology. Prior to joining Xenometrics, Phil was Senior Director of Pharmacology and Discovery Services at WIL Research for 10 years. He holds a BSc and MSc from the University of East London in the UK. In his current role Phil will be responsible for scheduling of resources and maintaining oversight of project timelines as well as interpretation and analysis of study results.
Jill Hopkins, BA, R.Q.A.P is Director of Quality Assurance at Xenometrics. She joined Xenometrics in 2014 after having worked at a specialist quality assurance firm. Jill is a graduate of University of Kansas and has successfully hosted several regultory inspections, including that of the FDA. In her current role, she is responsible for the company's continuous quality assurance training and CAPA program
Matthew Frick, BS is Director of Business Development of Xenometrics. Matt has over 12 years’ experience as a business development executive. Mr. Frick began his career as a Bioanalytical Scientist at Quintiles after being awarded his Bachelor of Science degree from Baker University. Subsequent to his laboratory tenure, Matt developed significant business relationships for companies such as Quintiles Preclinical and Exygen Research prior to him joining the management team at Xenometrics.
Joel Laner, BA, LLM is general counsel for Xenometrics. Mr. Laner has continuously practiced law for nearly 25 years in the business and real estate areas. His practice encompasses corporate, tax, and securities law. Mr. Laner has represented companies involved in a wide range of business activities including mergers, tax-free reorganizations, spin-offs, sales, work-outs, refinancings, public and private issues, consolidations, and joint ventures. He has handled employment agreements, deferred compensation arrangements, stock purchase and phantom stock plans, business formations and liquidations, and franchising and licensing arrangements.